. . . . . . "Humans and other mammals"@en . . . . "mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "* 53 mL/min [healthy]"@en . . " "@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "approved"@en . . . . "Cetirizin"@en . . . . . . . . . . . . . "A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. [PubChem]"@en . . "Manne Reddy, \"Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof.\" U.S. Patent US20040186112, issued September 23, 2004."@en . "83881-51-0"@en . . . . . "Cetirizine"@en . . . . "Somnolence (sleepiness or unusual drowsiness), restlessness, irritability"@en . "Avoid alcohol."@en . "Take without regard to meals."@en . . "8.3 hours"@en . . "Cetirizina"@en . . . . . . . . . . . "Cetirizinum"@en . . . . . . . . . . . "For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria"@en . . . . . . . . . . "Cetirizine competes with histamine for binding at H₁-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain."@en . . "Very high (93%) plasma protein binding"@en .